Comparison between Paras Healthcare IPO and Rubicon Research IPO.
Paras Healthcare IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Rubicon Research IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Paras Healthcare IPO is up to ₹0.00 Cr whereas the issue size of the Rubicon Research IPO is up to ₹1,377.68 Cr. The final issue price of Paras Healthcare IPO is and of Rubicon Research IPO is ₹485.00 per share.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ₹461.00 per share | |
| Issue Price (Upper) | ₹485.00 per share | |
| Issue Price (Final) | ₹485.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹46.00 per share | |
| Market Lot Size | 30 shares | |
| Fresh Issue Size | 0 shares | 1,03,13,058 shares |
| Fresh Issue Size (Amount) | up to ₹400.00 Cr | up to ₹500.18 Cr |
| OFS Issue Size | 1,49,74,010 shares | 1,80,92,783 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹877.50 Cr |
| Issue Size Total | 0 shares | 2,84,05,841 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹1,377.68 Cr |
Paras Healthcare IPO opens on , while Rubicon Research IPO opens on Oct 09, 2025. The closing date of Paras Healthcare IPO and Rubicon Research IPO is , and Oct 13, 2025, respectively.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| Anchor Bid Date | Oct 08, 2025 | |
| Issue Open | Oct 09, 2025 | |
| Issue Close | Oct 13, 2025 | |
| Basis Of Allotment (Tentative) | Oct 14, 2025 | |
| Initiation of Refunds (Tentative) | Oct 15, 2025 | |
| Credit of Share (Tentative) | Oct 15, 2025 | |
| Listing date (Tentative) | Oct 16, 2025 | |
| Anchor Lockin End date 1 | Nov 12, 2025 | |
| Anchor Lockin End date 2 | Jan 11, 2026 |
Paras Healthcare IPO P/E ratio is , as compared to Rubicon Research IPO P/E ratio of 55.75.
| Paras Healthcare IPO | Rubicon Research IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)Rubicon Research Ltd.'s revenue increased by 49% and profit after tax (PAT) rose by 48% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 75.32 | 75.71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 59.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 55.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹7990.21 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 29.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 26.45% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.73 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹8.70 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 29.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Paras Healthcare IPO Retail Individual Investors (RII) are offered while in Rubicon Research IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in Paras Healthcare IPO and 85,09,794 shares in Rubicon Research IPO.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,27,64,691 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 85,09,794 shares | |
| NII | 42,54,896 shares | |
| RII | 28,36,597 shares | |
| Employee | 39,863 shares | |
| Others | ||
| Total | 2,84,05,841 shares |
Paras Healthcare IPO subscribed in total, whereas Rubicon Research IPO subscribed 109.35x.
| Paras Healthcare IPO | Rubicon Research IPO | |
|---|---|---|
| QIB (times) | 137.09x | |
| NII (times) | 102.70x | |
| Big NII (times) | 117.77x | |
| Small NII (times) | 72.57x | |
| RII (times) | 37.40x | |
| Employee (times) | 17.68x | |
| Other (times) | ||
| Total (times) | 109.35x |
